| Biomarker ID | 395 |
| PMID | 19047106 |
| Year | 2008 |
| Biomarker | CCL4 |
| Biomarker Basis | Concentration Based (ng/mg) |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 2.16 (95% CI: 1.19-3.91) |
| Effect on Pathways | Pathways Include:- Selective expression of chemokine receptors during T-cell polarization, Pertussis toxin-insensitive CCR5 signaling in macrophageBinding of chemokines to chemokine receptors, Cytosolic DNA-sensing pathway ,Thymic stromal lymphopoietin (TSLP) pathway |
| Experiment | Biochemical Recurrence Vs No Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 180 patients were taken into the study. 82 patients developed reccurance within 5 years and 98 age matched controls (PCA with no recurrance). |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.011 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | Univariate Analysis |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CCL4 |